Press Releases Pacira BioSciences, Inc.

Stocks

PCRX

US6951271005

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-07-14 pm EDT			5-day change	1st Jan Change
25.01 ^USD	-2.08%		-3.14%	-3.36%

Jul. 01	Pacira BioSciences Announces UnitedHealthcare Provides Separate Reimbursement For EXPAREL	CI
Jul. 01	Pacira BioSciences' Exparel Now Separately Reimbursed by UnitedHealthcare Across Outpatient Settings	MT

Press Releases

Jul. 09	Pacira BioSciences Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	AQ
Jul. 08	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
Jul. 01	Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®	GL
Jul. 01	Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®	AQ
Jun. 30	Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet	GL
Jun. 01	Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees	PR
May. 28	Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira’s Director Nominees	GL
May. 27	Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees	GL
May. 27	Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty	GL
May. 27	Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty	AQ
May. 26	Pacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property Strategy	GL
May. 22	A Reno Biotech Just Rang the Nasdaq Bell — Here’s Why the Whole Regenerative-Medicine Tape Is Worth Watching	AQ
May. 20	Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockholders	GL
May. 13	Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences	GL
May. 13	Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences	AQ
May. 12	Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees	GL
May. 08	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
May. 05	Pacira BioSciences Mails Letter to Stockholders	GL
Apr. 30	Pacira BioSciences : Corporate Sustainability Report (pacira corporate sustainability report 2024 v1 20260430)	PU
Apr. 30	Pacira BioSciences : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
Apr. 30	Pacira BioSciences : PCRX 1Q26 Earnings Presentation FINAL	PU
Apr. 30	Pacira: Q1 Earnings Snapshot	AQ
Apr. 30	Pacira BioSciences Reports First Quarter 2026 Financial Results	GL
Apr. 28	Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders	GL
Apr. 27	Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty	GL